One makes $125,000.

The other makes $400,000.

That might sound extreme, but responses to the MDR Compensation Index show just how differently performance can be rewarded across medical device sales.

It raises a bigger question than what the average rep makes:

What is your performance actually worth?

This week, we’re looking at the relationship between quota attainment and compensation, why OTE may be one of the least useful numbers when evaluating a new job, and why recent investments in surgical robotics point toward a broader battle over who owns the technology ecosystem inside the OR.

Let’s get into it.

In theory, medical device sales compensation is pretty straightforward.

Sell more. Beat quota. Make more money.

The MDR Compensation Index suggests reality is more complicated.

We analyzed the 68 anonymous compensation submissions collected so far. Of those respondents, 56 provided usable quota attainment data.

The median quota attainment across that group was 104%.

But when we compared quota performance with reported W-2 compensation, something interesting emerged.

Performance matters.

But performance alone does not explain what someone earns.

Consider some actual anonymous responses from the dataset:

Among respondents reporting $400K+ in W-2 compensation who also reported quota attainment, median attainment was 120%.

High performance clearly shows up among many of the highest earners.

But the reverse isn’t necessarily true.

Several respondents significantly exceeded quota while earning well below $200K.

One respondent reported 124% attainment and $150K to $174,999 in W-2 compensation.

Another reported 125% attainment and $100K to $124,999.

Meanwhile, another respondent at the same 125% attainment reported $400K+.

Same reported percentage of quota.

More than a quarter-million-dollar difference in compensation brackets.

The MDR data cannot establish causation, but it points toward something experienced reps already understand intuitively.

Quota attainment doesn’t exist in a vacuum.

Your role matters.

Your specialty matters.

Your compensation structure matters.

Your experience matters.

And perhaps most importantly, the opportunity you’re attached to matters.

That could mean the territory, existing business, product economics, commission rates, accelerators, market maturity or how the company sets quota in the first place.

Our dataset isn’t large enough to isolate all of those variables reliably yet.

But it is large enough to challenge one assumption:

Being good at the job and being in a good economic opportunity are not necessarily the same thing.

And that leads directly to one of the most important career decisions a rep can make.

A recruiter calls you.

$250K OTE. Car allowance. Equity. Accelerators. President’s Club.

Sounds great.

There’s just one problem.

OTE doesn’t tell you whether you’re actually going to make $250,000.

It tells you what the compensation plan says you can make under a specific set of assumptions.

The territory determines whether those assumptions are realistic.

The compensation data above illustrates why that distinction matters.

Two people can perform at roughly the same percentage of quota and earn dramatically different amounts of money.

So the next time you’re evaluating a medical device opportunity, don’t just ask:

What’s the OTE?

Ask what sits underneath it:

OTE matters.

Of course it does.

But a $300K OTE attached to an unrealistic quota, deteriorating territory and constantly changing compensation plan may be worth less than a $225K OTE attached to a healthy market with achievable targets and strong accelerators.

When evaluating your next move, don’t just compare compensation plans.

Compare the economic opportunity you’re stepping into.

You've worked hard to fund your portfolio — your investment strategy should work just as hard to maximize your after-tax returns.

On September 17, join Range's CFPs and CPAs live for the practical moves that put more of your returns back in your pocket.

What we'll cover:

Range is all-in-one AI wealth management — tax, investments, retirement, and estate in one place. Bring your questions for the live Q&A. Free to attend, and seats are limited.

Reserve your spot today

^{This webinar is for informational purposes only and does not constitute investment advice or a recommendation to buy, hold, or sell any security. Forward-looking statements involve risks and uncertainties. Past performance is not indicative of future results. Range defines "high earners" as households with income over $300k.}

Two major surgical robotics announcements landed on the same day this month.

They weren’t small.

On September 1, Medtronic announced an approximately $700 million investment in Cornerstone Robotics. The agreement includes rights to distribute Cornerstone’s Sentire surgical system in select markets outside the U.S. where it is approved. Medtronic plans to position Sentire alongside its Hugo robotic-assisted surgery system.  

That same day, Enovis announced a binding offer to acquire eCential Robotics, a developer of surgical robotics and enabling technology. The deal values eCential at €155 million upfront enterprise value, with additional contingent consideration tied to milestones, and is expected to close by year-end subject to the required process and regulatory approvals.  

Two different deals.

One bigger trend.

Medtronic isn’t abandoning Hugo.

It’s adding another robotic platform to its portfolio.

The company specifically describes Sentire and Hugo as complementary systems and ties them into its broader connected surgical ecosystem.  

Enovis is making a similar ecosystem argument in orthopedics.

The company says eCential would expand its ASTRA enabling technology platform with robotic automation capabilities and create a broader integrated set of precision tools in the OR.  

This isn’t proof that every surgical company needs a robot.

But it does illustrate where major manufacturers believe value is being created.

Not simply in another implant.

In the platform around the procedure.

Planning. Navigation. Robotics. Instrumentation. Implants. Software. Data. Workflow.

The more pieces of that ecosystem a manufacturer controls, the deeper its potential relationship with the surgeon and health system.

This is where things get interesting.

For years, a rep could build a career around knowing a product category better than almost anyone else in the room.

That expertise still matters.

But the commercial skill set required to sell a broader technology ecosystem can be different.

You’re potentially selling to surgeons, administrators, OR leadership, finance, IT and capital committees.

The sales cycle can get longer.

The stakeholders multiply.

The conversation moves beyond:

“Why is my implant better?”

toward:

“Why should your hospital build part of its surgical workflow around our platform?”

That’s a very different sale.

And potentially a very different career opportunity.

The Medtronic and Enovis announcements don’t tell us exactly how field roles or compensation structures will change.

Any claim that they will would be speculation.

But they reinforce a direction worth watching:

The companies fighting for the future of the OR increasingly appear interested in owning more of the procedure, not just supplying one component of it.

For reps deciding where to build the next five or ten years of their careers, that matters.

There is a common thread running through all three stories this week.

Your performance matters.

But the environment in which that performance occurs matters too.

A rep can crush quota in a weak compensation structure.

Another can hit plan in an exceptional territory.

A company can sell an excellent standalone product.

Another can control an increasingly integrated technology platform.

Talent matters.

Execution matters.

But opportunity matters too.

The difficult part of building a great career in medical device sales is figuring out where those three things intersect.

The MDR Compensation Index is built entirely from anonymous submissions from people working across medical device sales.

Every additional response helps us dig deeper into compensation by role, specialty, experience, quota attainment and compensation structure.

Contribute anonymously to the MDR Compensation Index

And if you haven’t already:

Download the free 2026 Medical Device Sales Compensation Report

Individual responses are never published with personally identifying information.